Do you know the prevalence of triple-negative breast cancer? How about the patient makeup in the START A and START B trials, which tested hypofractionated radiotherapy for breast cancer? Answer these questions and more.
Question 1:
Answer and Question 2 on Next Page »
The correct answer is D. Refer to medical oncologist to discuss an anti-estrogen risk reduction agent (eg, tamoxifen)
Question 2:
Answer and Question 3 on Next Page »
The correct answer is D. Some women with ductal carcinoma in situ were included in these trials
Question 3:
Answer and Question 4 on Next Page »
The correct answer is B. 15% to 20%
Question 4:
Answer and Question 5 on Next Page »
The correct answer is A. The majority of tumors are estrogen-receptor positive
Question 5:
Answer on Next Page »
The correct answer is D. Germline BRCA1- or BRCA2-mutated tumor
